PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28655148-4 2017 Common functional polymorphisms have been described in the MnSOD gene [rs4880, NM_000636.3:c.47 T > C, alanine (ALA) to valine (Val)] and in the CAT promoter region [rs1001179, NG_013339.1:g.4760 C > T]. Valine 123-129 superoxide dismutase 2 Homo sapiens 59-64 30225256-9 2018 Results: The MnSOD Val/Ala+Ala/Ala genotype was significantly associated with an increased risk of CAD compared to the Val/Val genotype (OR = 1.86, 95% CI = 1.15-3.01). Valine 19-22 superoxide dismutase 2 Homo sapiens 13-18 30225256-9 2018 Results: The MnSOD Val/Ala+Ala/Ala genotype was significantly associated with an increased risk of CAD compared to the Val/Val genotype (OR = 1.86, 95% CI = 1.15-3.01). Valine 119-122 superoxide dismutase 2 Homo sapiens 13-18 30225256-9 2018 Results: The MnSOD Val/Ala+Ala/Ala genotype was significantly associated with an increased risk of CAD compared to the Val/Val genotype (OR = 1.86, 95% CI = 1.15-3.01). Valine 119-122 superoxide dismutase 2 Homo sapiens 13-18 28655148-4 2017 Common functional polymorphisms have been described in the MnSOD gene [rs4880, NM_000636.3:c.47 T > C, alanine (ALA) to valine (Val)] and in the CAT promoter region [rs1001179, NG_013339.1:g.4760 C > T]. Valine 131-134 superoxide dismutase 2 Homo sapiens 59-64 27325180-4 2016 The rs4880 encodes Ala16Val in SOD2 and the Val variant has been demonstrated to be functionally less efficient than the Ala variant. Valine 24-27 superoxide dismutase 2 Homo sapiens 31-35 26882122-3 2016 In humans, there is a gene polymorphism where a change of alanine (Ala) to valine (Val) occurs at the 16th amino acid (Ala16Val-SOD2). Valine 75-81 superoxide dismutase 2 Homo sapiens 128-132 26882122-3 2016 In humans, there is a gene polymorphism where a change of alanine (Ala) to valine (Val) occurs at the 16th amino acid (Ala16Val-SOD2). Valine 83-86 superoxide dismutase 2 Homo sapiens 128-132 26400460-13 2015 The rs4880 T > C substitution results in a Val > Ala amino acid change at position 16 of the MnSOD mitochondrial targeting sequence. Valine 46-49 superoxide dismutase 2 Homo sapiens 99-104 27141263-6 2016 This SNP changes the amino acid at position 16 from valine (Val) to alanine (Ala), which has been shown to cause a conformational change in the target sequence of manganese superoxide dismutase (MnSOD) and also affects MnSOD activity in mitochondria. Valine 52-58 superoxide dismutase 2 Homo sapiens 163-193 27141263-6 2016 This SNP changes the amino acid at position 16 from valine (Val) to alanine (Ala), which has been shown to cause a conformational change in the target sequence of manganese superoxide dismutase (MnSOD) and also affects MnSOD activity in mitochondria. Valine 52-58 superoxide dismutase 2 Homo sapiens 195-200 27141263-6 2016 This SNP changes the amino acid at position 16 from valine (Val) to alanine (Ala), which has been shown to cause a conformational change in the target sequence of manganese superoxide dismutase (MnSOD) and also affects MnSOD activity in mitochondria. Valine 52-58 superoxide dismutase 2 Homo sapiens 219-224 27141263-6 2016 This SNP changes the amino acid at position 16 from valine (Val) to alanine (Ala), which has been shown to cause a conformational change in the target sequence of manganese superoxide dismutase (MnSOD) and also affects MnSOD activity in mitochondria. Valine 60-63 superoxide dismutase 2 Homo sapiens 163-193 27141263-6 2016 This SNP changes the amino acid at position 16 from valine (Val) to alanine (Ala), which has been shown to cause a conformational change in the target sequence of manganese superoxide dismutase (MnSOD) and also affects MnSOD activity in mitochondria. Valine 60-63 superoxide dismutase 2 Homo sapiens 195-200 27141263-6 2016 This SNP changes the amino acid at position 16 from valine (Val) to alanine (Ala), which has been shown to cause a conformational change in the target sequence of manganese superoxide dismutase (MnSOD) and also affects MnSOD activity in mitochondria. Valine 60-63 superoxide dismutase 2 Homo sapiens 219-224 25753816-3 2015 In humans, a single nucleotide polymorphism (SNP) is present in the enzyme manganese superoxide dismutase (SOD2), localized in codon 16 (rs4880), which can either be an alanine (A) or valine (V). Valine 184-190 superoxide dismutase 2 Homo sapiens 107-111 25858271-4 2015 METHOD: 278 (136M:142F) T1DM patients and 135 (72M:63F) normal, healthy controls were investigated for SOD-2 polymorphism in the mitochondrial targeting sequence with Ala/Val (C-9T) substitution. Valine 171-174 superoxide dismutase 2 Homo sapiens 103-108 25858271-10 2015 CONCLUSION: The SNP in SOD-2 results in a substitution of C to T, which causes an amino acid change from alanine to valine. Valine 116-122 superoxide dismutase 2 Homo sapiens 23-28 25662905-6 2015 RESULTS: Among patients who underwent RT in the test cohort, there was a significant association between 3 of the 7 SOD2 SNPs and lethal prostate cancer: rs6917589 (overall P = .006), rs2758331 (P = .04) and the functional valine to alanine polymorphism in rs4880 (P = .04). Valine 223-229 superoxide dismutase 2 Homo sapiens 116-120 24610415-5 2014 Patients with HCV and normal, healthy controls were investigated for a superoxide dismutase (SOD-2) polymorphism in the mitochondrial targeting sequence with Ala/Val (C-9T) substitution. Valine 162-165 superoxide dismutase 2 Homo sapiens 93-98 25372290-7 2014 The predicted mean percentages of the subjects with gamma-GT elevation were about 2- to 3-fold, 3- to 4-fold and 4- to 8-fold greater in patients with the SOD2 Val/Val genotype but without any intellectual disability, those with the SOD2 Val/Ala or Ala/Ala genotype and intellectual disability and those with the SOD2 Val/Val genotype and intellectual disability, respectively, compared to those with the SOD2 Val/Ala or Ala/Ala genotype without intellectual disability. Valine 160-163 superoxide dismutase 2 Homo sapiens 155-159 21351093-11 2012 Patients carrying the high activity Ala/Ala genotype in SOD2 (rs4880) had significantly poorer PFS than Val allele carriers in the group treated by cyclophosphamide but not hormonal regimens (p = 0.004). Valine 104-107 superoxide dismutase 2 Homo sapiens 56-60 24587799-9 2014 There was a significant difference in the MnSOD genotype distributions between the RCC patients and the controls in terms of Ala/Ala+Ala/Val and Val/Val genotypes (P = 0.039). Valine 137-140 superoxide dismutase 2 Homo sapiens 42-47 24587799-9 2014 There was a significant difference in the MnSOD genotype distributions between the RCC patients and the controls in terms of Ala/Ala+Ala/Val and Val/Val genotypes (P = 0.039). Valine 145-148 superoxide dismutase 2 Homo sapiens 42-47 24587799-9 2014 There was a significant difference in the MnSOD genotype distributions between the RCC patients and the controls in terms of Ala/Ala+Ala/Val and Val/Val genotypes (P = 0.039). Valine 145-148 superoxide dismutase 2 Homo sapiens 42-47 22688013-2 2012 The superoxide dismutase manganese dependent (SOD2) catalyzes O(2)(-) in H(2)O(2) into mitochondria and is encoded by a single gene that presents a common polymorphism that results in the replacement of alanine (A) with a valine (V) in the 16 codon. Valine 222-228 superoxide dismutase 2 Homo sapiens 46-50 23967348-6 2013 Both the significant adjusted OR of 4.30 (95% CI, 1.23-15.03) and 4.53 (95% CI, 1.52-13.51) were observed in SOD2 Ala/Ala and Val/Ala compared to Val/Val and in SOD2 Ala/Ala compared to Val/Ala compared to Val/Val genetic analysis in the high chemical sensitivity case-control study. Valine 126-129 superoxide dismutase 2 Homo sapiens 109-113 23967348-6 2013 Both the significant adjusted OR of 4.30 (95% CI, 1.23-15.03) and 4.53 (95% CI, 1.52-13.51) were observed in SOD2 Ala/Ala and Val/Ala compared to Val/Val and in SOD2 Ala/Ala compared to Val/Ala compared to Val/Val genetic analysis in the high chemical sensitivity case-control study. Valine 126-129 superoxide dismutase 2 Homo sapiens 161-165 23967348-6 2013 Both the significant adjusted OR of 4.30 (95% CI, 1.23-15.03) and 4.53 (95% CI, 1.52-13.51) were observed in SOD2 Ala/Ala and Val/Ala compared to Val/Val and in SOD2 Ala/Ala compared to Val/Ala compared to Val/Val genetic analysis in the high chemical sensitivity case-control study. Valine 146-149 superoxide dismutase 2 Homo sapiens 109-113 23967348-6 2013 Both the significant adjusted OR of 4.30 (95% CI, 1.23-15.03) and 4.53 (95% CI, 1.52-13.51) were observed in SOD2 Ala/Ala and Val/Ala compared to Val/Val and in SOD2 Ala/Ala compared to Val/Ala compared to Val/Val genetic analysis in the high chemical sensitivity case-control study. Valine 146-149 superoxide dismutase 2 Homo sapiens 161-165 23967348-6 2013 Both the significant adjusted OR of 4.30 (95% CI, 1.23-15.03) and 4.53 (95% CI, 1.52-13.51) were observed in SOD2 Ala/Ala and Val/Ala compared to Val/Val and in SOD2 Ala/Ala compared to Val/Ala compared to Val/Val genetic analysis in the high chemical sensitivity case-control study. Valine 146-149 superoxide dismutase 2 Homo sapiens 109-113 23967348-6 2013 Both the significant adjusted OR of 4.30 (95% CI, 1.23-15.03) and 4.53 (95% CI, 1.52-13.51) were observed in SOD2 Ala/Ala and Val/Ala compared to Val/Val and in SOD2 Ala/Ala compared to Val/Ala compared to Val/Val genetic analysis in the high chemical sensitivity case-control study. Valine 146-149 superoxide dismutase 2 Homo sapiens 161-165 23967348-6 2013 Both the significant adjusted OR of 4.30 (95% CI, 1.23-15.03) and 4.53 (95% CI, 1.52-13.51) were observed in SOD2 Ala/Ala and Val/Ala compared to Val/Val and in SOD2 Ala/Ala compared to Val/Ala compared to Val/Val genetic analysis in the high chemical sensitivity case-control study. Valine 146-149 superoxide dismutase 2 Homo sapiens 109-113 23967348-6 2013 Both the significant adjusted OR of 4.30 (95% CI, 1.23-15.03) and 4.53 (95% CI, 1.52-13.51) were observed in SOD2 Ala/Ala and Val/Ala compared to Val/Val and in SOD2 Ala/Ala compared to Val/Ala compared to Val/Val genetic analysis in the high chemical sensitivity case-control study. Valine 146-149 superoxide dismutase 2 Homo sapiens 161-165 23967348-6 2013 Both the significant adjusted OR of 4.30 (95% CI, 1.23-15.03) and 4.53 (95% CI, 1.52-13.51) were observed in SOD2 Ala/Ala and Val/Ala compared to Val/Val and in SOD2 Ala/Ala compared to Val/Ala compared to Val/Val genetic analysis in the high chemical sensitivity case-control study. Valine 146-149 superoxide dismutase 2 Homo sapiens 109-113 23967348-6 2013 Both the significant adjusted OR of 4.30 (95% CI, 1.23-15.03) and 4.53 (95% CI, 1.52-13.51) were observed in SOD2 Ala/Ala and Val/Ala compared to Val/Val and in SOD2 Ala/Ala compared to Val/Ala compared to Val/Val genetic analysis in the high chemical sensitivity case-control study. Valine 146-149 superoxide dismutase 2 Homo sapiens 161-165 23967348-6 2013 Both the significant adjusted OR of 4.30 (95% CI, 1.23-15.03) and 4.53 (95% CI, 1.52-13.51) were observed in SOD2 Ala/Ala and Val/Ala compared to Val/Val and in SOD2 Ala/Ala compared to Val/Ala compared to Val/Val genetic analysis in the high chemical sensitivity case-control study. Valine 146-149 superoxide dismutase 2 Homo sapiens 109-113 23967348-6 2013 Both the significant adjusted OR of 4.30 (95% CI, 1.23-15.03) and 4.53 (95% CI, 1.52-13.51) were observed in SOD2 Ala/Ala and Val/Ala compared to Val/Val and in SOD2 Ala/Ala compared to Val/Ala compared to Val/Val genetic analysis in the high chemical sensitivity case-control study. Valine 146-149 superoxide dismutase 2 Homo sapiens 161-165 22807932-11 2012 MnSOD gene polymorphism Ala/Val may be a risk factor associated with more advanced breast cancer stage, and reduction of MnSOD activity may be a mechanism of the progression of benign to malignant tumors. Valine 28-31 superoxide dismutase 2 Homo sapiens 0-5 20501330-0 2010 Val-9Ala and Ile+58Thr polymorphism of MnSOD in Parkinson"s disease. Valine 0-3 superoxide dismutase 2 Homo sapiens 39-44 21619840-7 2011 SOD2 vitality in Ala(16) and Val(16) SOD2 transfected cells increased 2.51 and 2.71 times respectively (P < 0.01), but the difference between the two transfection groups was not statistically significant (P > 0.05). Valine 29-32 superoxide dismutase 2 Homo sapiens 0-4 21619840-7 2011 SOD2 vitality in Ala(16) and Val(16) SOD2 transfected cells increased 2.51 and 2.71 times respectively (P < 0.01), but the difference between the two transfection groups was not statistically significant (P > 0.05). Valine 29-32 superoxide dismutase 2 Homo sapiens 37-41 21619840-8 2011 After exposed to t-BHP, the majority of the untransfected and empty plasmid transfected cells sent "++" class bright fluorescence, while in Ala(16) and Val(16) SOD2 transfected groups, only about half cells sent "+-" ~ "+" level fuzzy fluorescence. Valine 152-155 superoxide dismutase 2 Homo sapiens 160-164 21053180-6 2010 However, a possible association with Hp1-1 and MnSOD Val/Ala genotypes suggests that, at least for the Brazilian population, polymorphisms related to oxidative stress should be more deeply investigated. Valine 53-56 superoxide dismutase 2 Homo sapiens 47-52 20802415-11 2010 CONCLUSIONS: The presence of valine at position 9 of the MnSOD signal peptide encoded by exon 2 is a risk factor for the occurrence of respiratory failure in the course of COPD in the Polish population. Valine 29-35 superoxide dismutase 2 Homo sapiens 57-62 20931825-18 2010 In the group of patients with COPD, Val/Val genotype at position 9 of MnSOD signal peptide is associated with more severe depression, anxiety as a trait and anxiety as a state in comparison with patients who have Val/Ala and Ala/Ala genotypes. Valine 36-39 superoxide dismutase 2 Homo sapiens 70-75 20931825-18 2010 In the group of patients with COPD, Val/Val genotype at position 9 of MnSOD signal peptide is associated with more severe depression, anxiety as a trait and anxiety as a state in comparison with patients who have Val/Ala and Ala/Ala genotypes. Valine 40-43 superoxide dismutase 2 Homo sapiens 70-75 20931825-18 2010 In the group of patients with COPD, Val/Val genotype at position 9 of MnSOD signal peptide is associated with more severe depression, anxiety as a trait and anxiety as a state in comparison with patients who have Val/Ala and Ala/Ala genotypes. Valine 40-43 superoxide dismutase 2 Homo sapiens 70-75 21574139-4 2011 Alanine versus valine polymorphism in the signal peptide of the Mn-SOD gene was evaluated using a primer pair to amplify a 107-bp fragment followed by digestion with the restriction enzyme NgoMIV. Valine 15-21 superoxide dismutase 2 Homo sapiens 64-70 21062213-8 2011 Distribution of MnSOD genotypes was 47% Val/Val-variant, 29.5% Ala/Val and 23.5% Ala/Ala-variants. Valine 40-43 superoxide dismutase 2 Homo sapiens 16-21 20206073-9 2010 In healthy subjects the MnSOD genotype distribution was as follows: alanine/alanine 1.9%, alanine/valine 28.3%, and valine/valine 69.8%, and in VSA patients the prevalence was: alanine/alanine 1.3%, alanine/valine 19.3%, and valine/valine 79.4%. Valine 116-122 superoxide dismutase 2 Homo sapiens 24-29 20206073-3 2010 There are two genetic variants of MnSOD arising from a substitution of an alanine for a valine in the signal peptide. Valine 88-94 superoxide dismutase 2 Homo sapiens 34-39 20206073-4 2010 We previously reported that the valine allele of MnSOD decreases the mitochondrial MnSOD (mtMnSOD) activity. Valine 32-38 superoxide dismutase 2 Homo sapiens 49-54 20206073-4 2010 We previously reported that the valine allele of MnSOD decreases the mitochondrial MnSOD (mtMnSOD) activity. Valine 32-38 superoxide dismutase 2 Homo sapiens 83-88 20206073-9 2010 In healthy subjects the MnSOD genotype distribution was as follows: alanine/alanine 1.9%, alanine/valine 28.3%, and valine/valine 69.8%, and in VSA patients the prevalence was: alanine/alanine 1.3%, alanine/valine 19.3%, and valine/valine 79.4%. Valine 98-104 superoxide dismutase 2 Homo sapiens 24-29 20206073-9 2010 In healthy subjects the MnSOD genotype distribution was as follows: alanine/alanine 1.9%, alanine/valine 28.3%, and valine/valine 69.8%, and in VSA patients the prevalence was: alanine/alanine 1.3%, alanine/valine 19.3%, and valine/valine 79.4%. Valine 116-122 superoxide dismutase 2 Homo sapiens 24-29 20206073-9 2010 In healthy subjects the MnSOD genotype distribution was as follows: alanine/alanine 1.9%, alanine/valine 28.3%, and valine/valine 69.8%, and in VSA patients the prevalence was: alanine/alanine 1.3%, alanine/valine 19.3%, and valine/valine 79.4%. Valine 116-122 superoxide dismutase 2 Homo sapiens 24-29 20206073-9 2010 In healthy subjects the MnSOD genotype distribution was as follows: alanine/alanine 1.9%, alanine/valine 28.3%, and valine/valine 69.8%, and in VSA patients the prevalence was: alanine/alanine 1.3%, alanine/valine 19.3%, and valine/valine 79.4%. Valine 116-122 superoxide dismutase 2 Homo sapiens 24-29 20206073-9 2010 In healthy subjects the MnSOD genotype distribution was as follows: alanine/alanine 1.9%, alanine/valine 28.3%, and valine/valine 69.8%, and in VSA patients the prevalence was: alanine/alanine 1.3%, alanine/valine 19.3%, and valine/valine 79.4%. Valine 116-122 superoxide dismutase 2 Homo sapiens 24-29 20206073-12 2010 CONCLUSION: The valine variant of MnSOD signal peptide increases the risk of VSA. Valine 16-22 superoxide dismutase 2 Homo sapiens 34-39 19467856-6 2009 However, we found that the MnSOD 9Ala allele was associated with an increased prostate cancer risk (Val/Ala versus Val/Val: odds ratio (OR)=1.1; 95% confidence intervals (CI): 1.0-1.3; Ala/Ala versus Val/Val: OR=1.3; 95% CI: 1.0-1.6; Val/Ala+Ala/Ala versus Val/Val: OR=1.2; 95% CI, 1.0-1.3). Valine 100-103 superoxide dismutase 2 Homo sapiens 27-32 19467856-6 2009 However, we found that the MnSOD 9Ala allele was associated with an increased prostate cancer risk (Val/Ala versus Val/Val: odds ratio (OR)=1.1; 95% confidence intervals (CI): 1.0-1.3; Ala/Ala versus Val/Val: OR=1.3; 95% CI: 1.0-1.6; Val/Ala+Ala/Ala versus Val/Val: OR=1.2; 95% CI, 1.0-1.3). Valine 115-118 superoxide dismutase 2 Homo sapiens 27-32 19467856-6 2009 However, we found that the MnSOD 9Ala allele was associated with an increased prostate cancer risk (Val/Ala versus Val/Val: odds ratio (OR)=1.1; 95% confidence intervals (CI): 1.0-1.3; Ala/Ala versus Val/Val: OR=1.3; 95% CI: 1.0-1.6; Val/Ala+Ala/Ala versus Val/Val: OR=1.2; 95% CI, 1.0-1.3). Valine 115-118 superoxide dismutase 2 Homo sapiens 27-32 19467856-6 2009 However, we found that the MnSOD 9Ala allele was associated with an increased prostate cancer risk (Val/Ala versus Val/Val: odds ratio (OR)=1.1; 95% confidence intervals (CI): 1.0-1.3; Ala/Ala versus Val/Val: OR=1.3; 95% CI: 1.0-1.6; Val/Ala+Ala/Ala versus Val/Val: OR=1.2; 95% CI, 1.0-1.3). Valine 115-118 superoxide dismutase 2 Homo sapiens 27-32 19467856-6 2009 However, we found that the MnSOD 9Ala allele was associated with an increased prostate cancer risk (Val/Ala versus Val/Val: odds ratio (OR)=1.1; 95% confidence intervals (CI): 1.0-1.3; Ala/Ala versus Val/Val: OR=1.3; 95% CI: 1.0-1.6; Val/Ala+Ala/Ala versus Val/Val: OR=1.2; 95% CI, 1.0-1.3). Valine 115-118 superoxide dismutase 2 Homo sapiens 27-32 19467856-7 2009 In addition, we found that the MnSOD Ala-9Ala genotype contributed to an increased breast cancer risk in premenopausal women who had low consumption of antioxidants (Ala/Ala versus Val/Ala+Val/Val: OR=2.6, 95% CI: 1.0-6.4 with low vitamin C consumption; OR=2.1, 95%CI: 1.3-3.4 with low vitamin E consumption and OR=2.9, 95%CI: 1.5-5.7 with low carotenoid consumption). Valine 181-184 superoxide dismutase 2 Homo sapiens 31-36 19467856-7 2009 In addition, we found that the MnSOD Ala-9Ala genotype contributed to an increased breast cancer risk in premenopausal women who had low consumption of antioxidants (Ala/Ala versus Val/Ala+Val/Val: OR=2.6, 95% CI: 1.0-6.4 with low vitamin C consumption; OR=2.1, 95%CI: 1.3-3.4 with low vitamin E consumption and OR=2.9, 95%CI: 1.5-5.7 with low carotenoid consumption). Valine 189-192 superoxide dismutase 2 Homo sapiens 31-36 19467856-7 2009 In addition, we found that the MnSOD Ala-9Ala genotype contributed to an increased breast cancer risk in premenopausal women who had low consumption of antioxidants (Ala/Ala versus Val/Ala+Val/Val: OR=2.6, 95% CI: 1.0-6.4 with low vitamin C consumption; OR=2.1, 95%CI: 1.3-3.4 with low vitamin E consumption and OR=2.9, 95%CI: 1.5-5.7 with low carotenoid consumption). Valine 189-192 superoxide dismutase 2 Homo sapiens 31-36 19509150-2 2009 A functional single-nucleotide polymorphism in codon 16 of SOD2 (rs4880), which encodes manganese superoxide dismutase, results in a substitution of valine by alanine (Val16Ala). Valine 149-155 superoxide dismutase 2 Homo sapiens 59-63 18784358-2 2008 The MnSOD allele with Val as amino acid 16 encodes a protein that has 30-40% lower activity compared with the MnSOD Ala variant, hence possibly increasing susceptibility to oxidative stress. Valine 22-25 superoxide dismutase 2 Homo sapiens 4-9 18977034-2 2008 The combined genotypes of T/T in NQO1 Pro187Ser and Val/Val in MnSOD Ala-9Val polymorphisms were found to be independently associated with a significantly higher risk of TD. Valine 52-55 superoxide dismutase 2 Homo sapiens 63-68 18977034-2 2008 The combined genotypes of T/T in NQO1 Pro187Ser and Val/Val in MnSOD Ala-9Val polymorphisms were found to be independently associated with a significantly higher risk of TD. Valine 56-59 superoxide dismutase 2 Homo sapiens 63-68 18784358-2 2008 The MnSOD allele with Val as amino acid 16 encodes a protein that has 30-40% lower activity compared with the MnSOD Ala variant, hence possibly increasing susceptibility to oxidative stress. Valine 22-25 superoxide dismutase 2 Homo sapiens 110-115 18683149-2 2008 METHODS: The Ala(-9)Val polymorphism of the Mn-SOD gene was determined by polymerase chain reaction and direct sequencing in 198 normal control subjects and 264 patients with type 2 diabetes mellitus, among them there were 139 non-diabetic retinopathy (NDR) subjects and 125 subjects with diabetic retinopathy (DR). Valine 20-23 superoxide dismutase 2 Homo sapiens 44-50 18760346-1 2008 The Ala/16Val dimorphism incorporates alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), modifying MnSOD mitochondrial import and activity. Valine 55-61 superoxide dismutase 2 Homo sapiens 111-141 18760346-1 2008 The Ala/16Val dimorphism incorporates alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), modifying MnSOD mitochondrial import and activity. Valine 55-61 superoxide dismutase 2 Homo sapiens 143-148 18760346-1 2008 The Ala/16Val dimorphism incorporates alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), modifying MnSOD mitochondrial import and activity. Valine 55-61 superoxide dismutase 2 Homo sapiens 161-166 18760346-1 2008 The Ala/16Val dimorphism incorporates alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), modifying MnSOD mitochondrial import and activity. Valine 10-13 superoxide dismutase 2 Homo sapiens 111-141 18760346-1 2008 The Ala/16Val dimorphism incorporates alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), modifying MnSOD mitochondrial import and activity. Valine 10-13 superoxide dismutase 2 Homo sapiens 143-148 18760346-1 2008 The Ala/16Val dimorphism incorporates alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), modifying MnSOD mitochondrial import and activity. Valine 10-13 superoxide dismutase 2 Homo sapiens 161-166 18646267-5 2008 A T-->C single nucleotide substitution, resulting in a Val-->Ala change at position 9 (Ala-9Val), which alters the secondary structure of the protein, has been noted to affect transport of MnSOD into the mitochondria. Valine 58-61 superoxide dismutase 2 Homo sapiens 195-200 18683149-7 2008 CONCLUSION: The Ala(-9)Val polymorphism in the Mn-SOD gene may not be related to the etiology of type 2 diabetes, but it seems to contribute to the development of diabetic retinopathy in Chinese type 2 diabetic patients. Valine 23-26 superoxide dismutase 2 Homo sapiens 47-53 17967822-5 2008 The mitochondrial MnSOD activities in leukocytes were 542.4 +/- 71.6 U/mg protein (alanine/alanine, n = 2), 302.0 +/- 94.9 U/mg protein (alanine/valine, n = 12), and 134.0 +/- 67.1 U/mg protein (valine/valine, n = 36; P < 0.0001 for non-valine/valine vs. valine/valine). Valine 195-201 superoxide dismutase 2 Homo sapiens 18-23 17967822-3 2008 We investigated the associations of the MnSOD polymorphism (valine-to-alanine in the mitochondrial-targeting domain) with its activity in leukocytes, with macrophage apoptosis by oxidized low-density lipoprotein (oxLDL), and with coronary artery disease (CAD). Valine 60-66 superoxide dismutase 2 Homo sapiens 40-45 17967822-5 2008 The mitochondrial MnSOD activities in leukocytes were 542.4 +/- 71.6 U/mg protein (alanine/alanine, n = 2), 302.0 +/- 94.9 U/mg protein (alanine/valine, n = 12), and 134.0 +/- 67.1 U/mg protein (valine/valine, n = 36; P < 0.0001 for non-valine/valine vs. valine/valine). Valine 145-151 superoxide dismutase 2 Homo sapiens 18-23 17967822-5 2008 The mitochondrial MnSOD activities in leukocytes were 542.4 +/- 71.6 U/mg protein (alanine/alanine, n = 2), 302.0 +/- 94.9 U/mg protein (alanine/valine, n = 12), and 134.0 +/- 67.1 U/mg protein (valine/valine, n = 36; P < 0.0001 for non-valine/valine vs. valine/valine). Valine 195-201 superoxide dismutase 2 Homo sapiens 18-23 17967822-5 2008 The mitochondrial MnSOD activities in leukocytes were 542.4 +/- 71.6 U/mg protein (alanine/alanine, n = 2), 302.0 +/- 94.9 U/mg protein (alanine/valine, n = 12), and 134.0 +/- 67.1 U/mg protein (valine/valine, n = 36; P < 0.0001 for non-valine/valine vs. valine/valine). Valine 195-201 superoxide dismutase 2 Homo sapiens 18-23 17967822-5 2008 The mitochondrial MnSOD activities in leukocytes were 542.4 +/- 71.6 U/mg protein (alanine/alanine, n = 2), 302.0 +/- 94.9 U/mg protein (alanine/valine, n = 12), and 134.0 +/- 67.1 U/mg protein (valine/valine, n = 36; P < 0.0001 for non-valine/valine vs. valine/valine). Valine 195-201 superoxide dismutase 2 Homo sapiens 18-23 17967822-5 2008 The mitochondrial MnSOD activities in leukocytes were 542.4 +/- 71.6 U/mg protein (alanine/alanine, n = 2), 302.0 +/- 94.9 U/mg protein (alanine/valine, n = 12), and 134.0 +/- 67.1 U/mg protein (valine/valine, n = 36; P < 0.0001 for non-valine/valine vs. valine/valine). Valine 195-201 superoxide dismutase 2 Homo sapiens 18-23 17967822-5 2008 The mitochondrial MnSOD activities in leukocytes were 542.4 +/- 71.6 U/mg protein (alanine/alanine, n = 2), 302.0 +/- 94.9 U/mg protein (alanine/valine, n = 12), and 134.0 +/- 67.1 U/mg protein (valine/valine, n = 36; P < 0.0001 for non-valine/valine vs. valine/valine). Valine 195-201 superoxide dismutase 2 Homo sapiens 18-23 18023606-5 2008 A valine (Val) to alanine (Ala) substitution at amino acid 9, mapping within the mitochondrion-targeting sequence of the MnSOD gene, has been associated with an increased cancer risk. Valine 2-8 superoxide dismutase 2 Homo sapiens 121-126 18023606-5 2008 A valine (Val) to alanine (Ala) substitution at amino acid 9, mapping within the mitochondrion-targeting sequence of the MnSOD gene, has been associated with an increased cancer risk. Valine 10-13 superoxide dismutase 2 Homo sapiens 121-126 17646272-5 2007 The higher activity Ala variant at SOD2 Ex2+24T>C (V16A), which has been hypothesized to suppress prostate carcinogenesis, was associated with elevation of prostate cancer risk in Caucasians (Val/Ala versus Val/Val: OR, 1.17; 95% CI, 0.97-1.42; Ala/Ala versus Val/Val: OR, 1.28; 95% CI, 1.03-1.60; P(trend) = 0.03). Valine 195-198 superoxide dismutase 2 Homo sapiens 35-39 17628794-4 2007 A valine (Val) to alanine (Ala) substitution at amino acid 16, occurring in the mitochondrial targeting sequence of the MnSOD gene, has been associated with an increase in urolithiasis risk. Valine 2-8 superoxide dismutase 2 Homo sapiens 120-125 17628794-4 2007 A valine (Val) to alanine (Ala) substitution at amino acid 16, occurring in the mitochondrial targeting sequence of the MnSOD gene, has been associated with an increase in urolithiasis risk. Valine 10-13 superoxide dismutase 2 Homo sapiens 120-125 17646272-5 2007 The higher activity Ala variant at SOD2 Ex2+24T>C (V16A), which has been hypothesized to suppress prostate carcinogenesis, was associated with elevation of prostate cancer risk in Caucasians (Val/Ala versus Val/Val: OR, 1.17; 95% CI, 0.97-1.42; Ala/Ala versus Val/Val: OR, 1.28; 95% CI, 1.03-1.60; P(trend) = 0.03). Valine 210-213 superoxide dismutase 2 Homo sapiens 35-39 17646272-5 2007 The higher activity Ala variant at SOD2 Ex2+24T>C (V16A), which has been hypothesized to suppress prostate carcinogenesis, was associated with elevation of prostate cancer risk in Caucasians (Val/Ala versus Val/Val: OR, 1.17; 95% CI, 0.97-1.42; Ala/Ala versus Val/Val: OR, 1.28; 95% CI, 1.03-1.60; P(trend) = 0.03). Valine 210-213 superoxide dismutase 2 Homo sapiens 35-39 17646272-5 2007 The higher activity Ala variant at SOD2 Ex2+24T>C (V16A), which has been hypothesized to suppress prostate carcinogenesis, was associated with elevation of prostate cancer risk in Caucasians (Val/Ala versus Val/Val: OR, 1.17; 95% CI, 0.97-1.42; Ala/Ala versus Val/Val: OR, 1.28; 95% CI, 1.03-1.60; P(trend) = 0.03). Valine 210-213 superoxide dismutase 2 Homo sapiens 35-39 17646272-5 2007 The higher activity Ala variant at SOD2 Ex2+24T>C (V16A), which has been hypothesized to suppress prostate carcinogenesis, was associated with elevation of prostate cancer risk in Caucasians (Val/Ala versus Val/Val: OR, 1.17; 95% CI, 0.97-1.42; Ala/Ala versus Val/Val: OR, 1.28; 95% CI, 1.03-1.60; P(trend) = 0.03). Valine 210-213 superoxide dismutase 2 Homo sapiens 35-39 16969494-0 2006 Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17beta1, COMT and MnSOD): possible protective role of MnSOD gene polymorphism Val/Ala and Ala/Ala in women that never breast fed. Valine 171-174 superoxide dismutase 2 Homo sapiens 147-152 16933053-1 2006 OBJECTIVE: A functional polymorphism at codon 16 (Alanine-to-Valine) of manganese superoxide dismutase (MnSOD) has been hypothesized to increase the risk of breast cancer and to modify the effects of oxidative stress. Valine 61-67 superoxide dismutase 2 Homo sapiens 72-102 16933053-1 2006 OBJECTIVE: A functional polymorphism at codon 16 (Alanine-to-Valine) of manganese superoxide dismutase (MnSOD) has been hypothesized to increase the risk of breast cancer and to modify the effects of oxidative stress. Valine 61-67 superoxide dismutase 2 Homo sapiens 104-109 17336594-1 2007 BACKGROUND & AIMS: A genetic dimorphism encodes for either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), and modulates its mitochondrial import and activity. Valine 80-86 superoxide dismutase 2 Homo sapiens 136-166 17336594-1 2007 BACKGROUND & AIMS: A genetic dimorphism encodes for either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), and modulates its mitochondrial import and activity. Valine 80-86 superoxide dismutase 2 Homo sapiens 168-173 17336594-1 2007 BACKGROUND & AIMS: A genetic dimorphism encodes for either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), and modulates its mitochondrial import and activity. Valine 88-91 superoxide dismutase 2 Homo sapiens 136-166 17336594-1 2007 BACKGROUND & AIMS: A genetic dimorphism encodes for either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), and modulates its mitochondrial import and activity. Valine 88-91 superoxide dismutase 2 Homo sapiens 168-173 17453961-2 2007 METHODS: Ala (GTT) or Val (GCT) polymorphism in the signal peptide of Mn-SOD gene was evaluated using a primer pair to amplify a 107-bp fragment followed by digestion with restriction enzyme NgoM IV. Valine 22-25 superoxide dismutase 2 Homo sapiens 70-76 17192491-4 2007 The present study aimed to determine whether a valine/alanine polymorphism in MnSOD (V16A, rs4880), alone or in combination with smoking, can contribute to development of diabetic nephropathy in 1,510 Finnish and Swedish patients with type 1 diabetes. Valine 47-53 superoxide dismutase 2 Homo sapiens 78-83 16543247-9 2006 In an analysis of manganese superoxide dismutase (SOD2 Val16Ala, rs1799725) Ala/Ala homozygotes, we observed moderately increased risks for B-cell lymphomas (OR=1.3, 95% CI=1.0-1.6; referent=Val/Val and Val/Ala) that was consistent across the B-cell subtypes. Valine 55-58 superoxide dismutase 2 Homo sapiens 50-54 17217237-12 2006 CONCLUSION: In the Polish population there is a statistically substantial association between schizophrenia incidence and the Val-9Val genotype in a gene for MnSOD. Valine 126-129 superoxide dismutase 2 Homo sapiens 158-163 16807759-7 2006 Our results suggest that Ala/Val polymorphism of the SOD2 gene could be associated with the risk of developing methamphetamine psychosis. Valine 29-32 superoxide dismutase 2 Homo sapiens 53-57 17217237-13 2006 Schizophrenic patients having a Val-9Val genotype in the gene for MnSOD have nearly a ten times higher risk for developing TD than schizophrenics not having this genotype. Valine 32-35 superoxide dismutase 2 Homo sapiens 66-71 17217237-14 2006 Risk for developing schizophrenia for people having the Val-9Val genotype in the gene for MnSOD is over three times higher than for people lacking this genotype. Valine 56-59 superoxide dismutase 2 Homo sapiens 90-95 16780268-16 2006 Risk for developing schizophrenia in people having Val-9Val genotype in a gene for MnSOD is over three times higher than for people not having this very genotype. Valine 51-54 superoxide dismutase 2 Homo sapiens 83-88 16084535-5 2006 In those with the MnSOD Val/Ala or Ala/Ala genotypes this regression coefficient was 1.480 (p=0.040), whereas for the MnSOD Val/Val genotype it was 0.088 (p=0.859). Valine 24-27 superoxide dismutase 2 Homo sapiens 18-23 16084535-6 2006 The higher regression coefficient was obtained for the subject group with the MnSOD Val/Ala or Ala/Ala genotype in combination with the MPO G/G genotype (p=0.012). Valine 84-87 superoxide dismutase 2 Homo sapiens 78-83 16847469-2 2006 In this study, we aim to investigate the manganese superoxide dismutase (MnSOD) polymorphism at nucleotide 47 as a result of the change of Ala to Val on the protein sequence in CPPS patients. Valine 146-149 superoxide dismutase 2 Homo sapiens 41-71 16847469-2 2006 In this study, we aim to investigate the manganese superoxide dismutase (MnSOD) polymorphism at nucleotide 47 as a result of the change of Ala to Val on the protein sequence in CPPS patients. Valine 146-149 superoxide dismutase 2 Homo sapiens 73-78 15864132-1 2005 A genetic dimorphism incorporates either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence (MTS) of manganese superoxide dismutase (MnSOD). Valine 58-64 superoxide dismutase 2 Homo sapiens 152-157 15951095-5 2005 A valine (Val) to alanine (Ala) substitution at amino acid -9, occurring in the MnSOD gene, has been associated with various disease risk. Valine 2-8 superoxide dismutase 2 Homo sapiens 80-85 15951095-5 2005 A valine (Val) to alanine (Ala) substitution at amino acid -9, occurring in the MnSOD gene, has been associated with various disease risk. Valine 10-13 superoxide dismutase 2 Homo sapiens 80-85 17491681-0 2005 Manganese superoxide dismutase alanine to valine polymorphism and risk of neuropathy and nephropathy in Egyptian type 1 diabetic patients. Valine 42-48 superoxide dismutase 2 Homo sapiens 0-30 15864132-1 2005 A genetic dimorphism incorporates either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence (MTS) of manganese superoxide dismutase (MnSOD). Valine 66-69 superoxide dismutase 2 Homo sapiens 152-157 15864132-4 2005 HuH7 human hepatoma cells were transfected with vectors encoding for the human Ala- or Val-MnSOD variants fused to a Myc-His-tag. Valine 87-90 superoxide dismutase 2 Homo sapiens 91-96 15864132-5 2005 The Ala-variant resulted in four-fold higher levels of the mature exogenous protein and MnSOD activity than the Val-variant. Valine 112-115 superoxide dismutase 2 Homo sapiens 88-93 15864132-9 2005 Much larger differences in the activity of the human Val- and Ala-MnSOD variants are observed in whole cells rather than after import experiments performed in vitro. Valine 53-56 superoxide dismutase 2 Homo sapiens 66-71 15933380-2 2005 Recent evidences suggest that a genetic dimorphism that encodes for either alanine or valine in superoxide dismutase (SOD2) is involved with oxidative stress. Valine 86-92 superoxide dismutase 2 Homo sapiens 118-122 15781667-2 2005 A polymorphism [valine (V) --> alanine (A)] of manganese superoxide dismutase (MnSOD), the primary antioxidant enzyme in mitochondria, has been recently associated with prostate cancer. Valine 16-22 superoxide dismutase 2 Homo sapiens 50-80 15781667-2 2005 A polymorphism [valine (V) --> alanine (A)] of manganese superoxide dismutase (MnSOD), the primary antioxidant enzyme in mitochondria, has been recently associated with prostate cancer. Valine 16-22 superoxide dismutase 2 Homo sapiens 82-87 15184255-3 2004 A valine (Val) to alanine (Ala) substitution at amino acid 16, occurring in the mitochondrial targeting sequence of the MnSOD gene, has been associated with an increase in breast cancer risk. Valine 2-8 superoxide dismutase 2 Homo sapiens 120-125 15331175-3 2004 For women carrying the MPO variant genotypes, the adjusted odds ratio of the SOD2 polymorphism (Val/Val vs. Ala/Ala) was 3.26 (95% CI, 1.55-6.83). Valine 96-99 superoxide dismutase 2 Homo sapiens 77-81 15331175-3 2004 For women carrying the MPO variant genotypes, the adjusted odds ratio of the SOD2 polymorphism (Val/Val vs. Ala/Ala) was 3.26 (95% CI, 1.55-6.83). Valine 100-103 superoxide dismutase 2 Homo sapiens 77-81 15765450-1 2005 BACKGROUND AND AIMS: A genetic dimorphism encodes for either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), and modulates its mitochondrial import. Valine 78-84 superoxide dismutase 2 Homo sapiens 134-164 15765450-1 2005 BACKGROUND AND AIMS: A genetic dimorphism encodes for either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), and modulates its mitochondrial import. Valine 78-84 superoxide dismutase 2 Homo sapiens 166-171 15765450-1 2005 BACKGROUND AND AIMS: A genetic dimorphism encodes for either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), and modulates its mitochondrial import. Valine 86-89 superoxide dismutase 2 Homo sapiens 134-164 15765450-1 2005 BACKGROUND AND AIMS: A genetic dimorphism encodes for either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence of manganese superoxide dismutase (MnSOD), and modulates its mitochondrial import. Valine 86-89 superoxide dismutase 2 Homo sapiens 166-171 15589819-2 2004 METHODS: Alanine or valine polymorphism in the signal peptide of Mn-SOD gene was evaluated using a primer pair to amplify a 107-bp fragment followed by digestion with NgoM IV. Valine 20-26 superoxide dismutase 2 Homo sapiens 65-71 15196853-5 2004 RESULTS: For SOD2, women with the TC (val/ala) or CC (ala/ala) genotypes were at increased risk [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.1-4.0]. Valine 38-41 superoxide dismutase 2 Homo sapiens 13-17 15184255-3 2004 A valine (Val) to alanine (Ala) substitution at amino acid 16, occurring in the mitochondrial targeting sequence of the MnSOD gene, has been associated with an increase in breast cancer risk. Valine 10-13 superoxide dismutase 2 Homo sapiens 120-125 12948282-6 2003 RESULTS: Men homozygous for the MnSOD ala allele had a 70% increase in risk over men homozygous for the val allele (odds ratio, OR = 1.72, 95% confidence interval, CI = 0.96-3.08, p = 0.07). Valine 104-107 superoxide dismutase 2 Homo sapiens 32-37 14704872-4 2003 We examined polymorphic markers Ala(-9)Val in SOD2 gene and Arg213Gly in SOD3 gene for possible relation to DPN in Russian type 1 diabetic patients. Valine 39-42 superoxide dismutase 2 Homo sapiens 46-50 12948282-8 2003 Although there was no difference in the association with disease stage, men homozygous for MnSOD ala (compared to MnSOD val/val or val/ala) showed a three-fold risk increase for high-grade tumors (OR = 2.72, 95% CI: 1.15-6.40, p = 0.02). Valine 120-123 superoxide dismutase 2 Homo sapiens 91-96 12948282-8 2003 Although there was no difference in the association with disease stage, men homozygous for MnSOD ala (compared to MnSOD val/val or val/ala) showed a three-fold risk increase for high-grade tumors (OR = 2.72, 95% CI: 1.15-6.40, p = 0.02). Valine 120-123 superoxide dismutase 2 Homo sapiens 114-119 12948282-8 2003 Although there was no difference in the association with disease stage, men homozygous for MnSOD ala (compared to MnSOD val/val or val/ala) showed a three-fold risk increase for high-grade tumors (OR = 2.72, 95% CI: 1.15-6.40, p = 0.02). Valine 124-127 superoxide dismutase 2 Homo sapiens 91-96 12948282-8 2003 Although there was no difference in the association with disease stage, men homozygous for MnSOD ala (compared to MnSOD val/val or val/ala) showed a three-fold risk increase for high-grade tumors (OR = 2.72, 95% CI: 1.15-6.40, p = 0.02). Valine 124-127 superoxide dismutase 2 Homo sapiens 114-119 12624725-1 2003 We evaluated the relationship of an alanine or valine polymorphism at amino acid sequence 16 [Val(16)Ala] of manganese superoxide dismutase (Mn-SOD) with diabetes and diabetic nephropathy in Japanese type 2 diabetic patients. Valine 47-53 superoxide dismutase 2 Homo sapiens 109-139 12618592-1 2003 A genetic dimorphism encodes for either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence (MTS) of human manganese superoxide dismutase (MnSOD) and has been reported to modulate the risk of some cancers, neurodegenerative diseases and severe alcoholic liver disease. Valine 57-63 superoxide dismutase 2 Homo sapiens 125-155 12618592-1 2003 A genetic dimorphism encodes for either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence (MTS) of human manganese superoxide dismutase (MnSOD) and has been reported to modulate the risk of some cancers, neurodegenerative diseases and severe alcoholic liver disease. Valine 57-63 superoxide dismutase 2 Homo sapiens 157-162 12618592-1 2003 A genetic dimorphism encodes for either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence (MTS) of human manganese superoxide dismutase (MnSOD) and has been reported to modulate the risk of some cancers, neurodegenerative diseases and severe alcoholic liver disease. Valine 65-68 superoxide dismutase 2 Homo sapiens 125-155 12618592-1 2003 A genetic dimorphism encodes for either alanine (Ala) or valine (Val) in the mitochondrial targeting sequence (MTS) of human manganese superoxide dismutase (MnSOD) and has been reported to modulate the risk of some cancers, neurodegenerative diseases and severe alcoholic liver disease. Valine 65-68 superoxide dismutase 2 Homo sapiens 157-162 12683635-9 2003 In Mn-SOD mRNA, Val at -9 position was varied to Ala in lymphocytes from two donors and three OSC cell lines, respectively. Valine 16-19 superoxide dismutase 2 Homo sapiens 3-9 12815947-0 2003 [Association of the SOD2 Ala(-9)Val and SOD3 Arg213Gly polymorphisms with diabetic polyneuropathy in patients with diabetes mellitus type 1]. Valine 32-35 superoxide dismutase 2 Homo sapiens 20-24 12624725-1 2003 We evaluated the relationship of an alanine or valine polymorphism at amino acid sequence 16 [Val(16)Ala] of manganese superoxide dismutase (Mn-SOD) with diabetes and diabetic nephropathy in Japanese type 2 diabetic patients. Valine 47-53 superoxide dismutase 2 Homo sapiens 141-147 11481695-5 2001 However, we identified a previously described polymorphism of the mitochondrial targeting sequence consisting of a C47T in exon 2 of SOD2, which results in an alanine to valine substitution. Valine 170-176 superoxide dismutase 2 Homo sapiens 133-137 12447859-2 2002 Recently, it has been reported that homozygosity for a valine to alanine substitution in the mitochondrial targeting sequence of manganese superoxide dismutase (Mn-SOD) represents a risk factor for severe ALD. Valine 55-61 superoxide dismutase 2 Homo sapiens 129-159 12447859-2 2002 Recently, it has been reported that homozygosity for a valine to alanine substitution in the mitochondrial targeting sequence of manganese superoxide dismutase (Mn-SOD) represents a risk factor for severe ALD. Valine 55-61 superoxide dismutase 2 Homo sapiens 161-167 12447859-6 2002 However, the carriers of the alanine Mn-SOD allele had titers of anti-MDA, anti-HER, and anti-OX-CL IgG comparable with heterozygotes and patients homozygous for the valine allele. Valine 166-172 superoxide dismutase 2 Homo sapiens 37-43 11836586-1 2002 Recently a T to C substitution in the mitochondrial targeting sequence of the manganese superoxide dismutase (MnSOD) gene was observed that changes the amino acid sequence of the protein from valine (V) to alanine (A) and is associated with a decreased defense capacity against oxidative stress. Valine 192-198 superoxide dismutase 2 Homo sapiens 78-108 11836586-1 2002 Recently a T to C substitution in the mitochondrial targeting sequence of the manganese superoxide dismutase (MnSOD) gene was observed that changes the amino acid sequence of the protein from valine (V) to alanine (A) and is associated with a decreased defense capacity against oxidative stress. Valine 192-198 superoxide dismutase 2 Homo sapiens 110-115 9973207-7 1999 Using a RFLP that distinguishes a valine (V) to alanine (A) change in the -9 position in the signal sequence of the protein for MnSOD, we characterized MnSOD genotypes in relation to breast cancer risk. Valine 34-40 superoxide dismutase 2 Homo sapiens 128-133 11299047-11 2001 CONCLUSIONS: Ala(-9)Val substitution in the Mn-SOD gene was associated with DN in a Russian population Valine 20-23 superoxide dismutase 2 Homo sapiens 44-50 11313317-2 2001 A genetic dimorphism encodes for either alanine or valine in the mitochondrial targeting sequence of manganese superoxide dismutase and could modulate its mitochondrial import. Valine 51-57 superoxide dismutase 2 Homo sapiens 101-131 9371904-3 1997 We used a novel polymorphic mutation at -9 position of the signal peptide of the Mn SOD precursor protein, which caused valine to alanine substitution. Valine 120-126 superoxide dismutase 2 Homo sapiens 81-87